share_log

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3:募資說明書
美股SEC公告 ·  07/31 12:37

Moomoo AI 已提取核心訊息

Panbela Therapeutics, Inc. has filed a prospectus supplement on July 30, 2024, to update and supplement information from its previous prospectus dated September 29, 2022. The supplement includes details from a current report filed on the same date, which discloses that Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., have entered into a Loan Agreement with USWM, LLC for a term loan of $1.5 million. The loan, which is due by the end of 2024 or upon the occurrence of certain financing events, carries an interest and premium totaling $375,000, with additional potential payments tied to the proceeds of a Qualifying Transaction, capped at $1 million. The proceeds from the loan are designated for specific uses, including payment to a contract research organization, working capital purposes, and...Show More
Panbela Therapeutics, Inc. has filed a prospectus supplement on July 30, 2024, to update and supplement information from its previous prospectus dated September 29, 2022. The supplement includes details from a current report filed on the same date, which discloses that Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., have entered into a Loan Agreement with USWM, LLC for a term loan of $1.5 million. The loan, which is due by the end of 2024 or upon the occurrence of certain financing events, carries an interest and premium totaling $375,000, with additional potential payments tied to the proceeds of a Qualifying Transaction, capped at $1 million. The proceeds from the loan are designated for specific uses, including payment to a contract research organization, working capital purposes, and related fees or expenses. The agreement also includes a first priority security interest in favor of the lender against the company's rights in an Asset Purchase Agreement. The company's common stock is quoted on the OTCQB under the symbol 'PBLA', with the last reported sales price being $0.35 per share as of July 29, 2024.
Panbela Therapeutics公司於2024年7月30日提交了一份招股書。該書更新並補充了2022年9月29日的招股書中的信息。補充內容包括同一日期提交的一份公司報告,並披露Panbela Therapeutics及其子公司Cancer Prevention Pharmaceuticals, Inc.與USWm, LLC簽署了一項貸款協議,貸款期限爲150萬美元。這項貸款將於2024年底或某些融資事件發生時到期,帶有375,000美元的利息和溢價,並額外支付與符合條件的交易收益相關的潛在款項,上限爲100萬美元。這筆貸款的收益將用於特定用途,包括支付合同研究組織、營運資金以及相關費用或支出。該協議還包括將優先安全利益歸還貸方,根據資產購買協議的公司權益。該公司的普通股在OTCQb上以“PBLA”爲標的,最近報告的銷售價格爲2024年7月29日的每股0.35美元。
Panbela Therapeutics公司於2024年7月30日提交了一份招股書。該書更新並補充了2022年9月29日的招股書中的信息。補充內容包括同一日期提交的一份公司報告,並披露Panbela Therapeutics及其子公司Cancer Prevention Pharmaceuticals, Inc.與USWm, LLC簽署了一項貸款協議,貸款期限爲150萬美元。這項貸款將於2024年底或某些融資事件發生時到期,帶有375,000美元的利息和溢價,並額外支付與符合條件的交易收益相關的潛在款項,上限爲100萬美元。這筆貸款的收益將用於特定用途,包括支付合同研究組織、營運資金以及相關費用或支出。該協議還包括將優先安全利益歸還貸方,根據資產購買協議的公司權益。該公司的普通股在OTCQb上以“PBLA”爲標的,最近報告的銷售價格爲2024年7月29日的每股0.35美元。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息